Zydus Cadila receives USFDA approval for Colesevelam Hydrochloride Tablets
Capital MarketZydus Cadila has received the final approval from the USFDA to market Colesevelam
Hydrochloride Tablets, (US RLD - Welchol), 625 mg. This medication is used along with a
proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in
the blood. Lowering cholesterol decreases the risk of heart disease and helps prevent strokes
and heart attacks. It will be manufactured at the group's formulations manufacturing facility at
SEZ, Ahmedabad.
The group now has 273 approvals and has so far filed over 360 ANDAs since the
commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
